Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
31. |
ECCT/25/05/13 | IVI CCV 002 A Phase II, randomized, controlled, age-descending study in adults and children to evaluate the safety and immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in cholera-endemic region |
Principal Investigator(s) 1. Walter Jaoko Site(s) in Kenya KAVI - Institute of Clinical Research, University of Nairobi |
View |
32. |
ECCT/25/05/10 | Field Evaluation for STI POC Evaluation of a Point-of-Care (PoC) diagnostic device to improve sexually Transmitted Infections Management and outcomes in Kenya: SERU PROTOCOL NO. NON KEMRI 5074 Enable GingerCannot connect to Ginger Check your internet connection or reload the browserDisable Ginger?How to use GingerRephraseRephrase with Ginger (Ctrl+Alt+E)Edit in GingerGinger is checking your text for mistakes...Disable Ginger in this text fieldDisable Ginger on this website× Enable GingerCannot connect to Ginger Check your internet connection or reload the browserDisable Ginger?How to use GingerRephraseRephrase with Ginger (Ctrl+Alt+E)Edit in GingerGinger is checking your text for mistakes...Disable Ginger in this text fieldDisable Ginger on this website× |
Principal Investigator(s) 1. Patricia Ongwen 2. Dismas Ouma 3. Rose Wafula Site(s) in Kenya International Centre for Reproductive Health -Kenya |
View |
33. |
ECCT/25/05/06 | Hibiscus 2 - Site 254 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Doreen Mutua Site(s) in Kenya 1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county) |
View |
34. |
ECCT/25/05/03 | Hibiscus 2 - Site 253 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Site 253 - International Cancer Institute (Uasin Gishu county) |
View |
35. |
ECCT/25/05/05 | Hibiscus 2 - Site 252 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county) |
View |